Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Cognition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Cognition's position in the market.
Alpha Cognition (Nasdaq: ACOG) announced that underwriters have partially exercised their over-allotment option to purchase an additional 488,506 common shares at US$5.75 per share, generating US$2.8 million in additional gross proceeds. Following this exercise, the company's total offering reached 9,184,159 shares, raising approximately US$52.8 million in gross proceeds before deducting expenses.
The company's shares began trading on The Nasdaq Capital Market on November 12, 2024, under ticker ACOG. Proceeds will fund ZUNVEYL™ commercialization for Alzheimer's Disease, pipeline product development, commercial CMC activities, and working capital. Titan Partners Group is serving as Sole Bookrunner for the offering.
Alpha Cognition (NASDAQ: ACOG) has announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective at the close of trading on December 17, 2024. The company's common shares will continue to trade exclusively on the Nasdaq Capital Market under the symbol 'ACOG'. This decision comes in connection with the company's existing Nasdaq listing.
Alpha Cognition (ACOG) announced positive interim preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), specifically focusing on blast trauma injuries relevant to military personnel. The study, conducted in collaboration with the Seattle Institute of Biomedical and Clinical Research and supported by the US Department of Defense, showed promising results in a rodent model.
The interim data revealed that ALPHA-1062 administration following three consecutive days of blast-induced mTBI reduced neuroinflammation markers and neuropathology. High doses demonstrated reduced myeloid cell activation across multiple brain regions and decreased midbrain astrogliosis one month after blast. Final study results, including neuropathology and neurobehavioral data analysis, are expected in Q2/2025.
Alpha Cognition (NASDAQ: ACOG) reported Q3 2024 financial results and corporate updates. The company received FDA approval for ZUNVEYL, an Alzheimer's disease treatment, with commercial launch planned for Q1 2025. Key highlights include: $4.5M raised in bridge financing, successful manufacturing stability tests extending ZUNVEYL's shelf life to 24 months, and NASDAQ listing preparation. Financial results show Q3 2024 R&D expenses of $1.0M (down from $1.4M in Q3 2023), G&A expenses of $1.2M (up from $0.8M), and a net loss of $1.9M ($0.31 per share). Cash position stands at $3.7M as of September 30, 2024.
Alpha Cognition (ACOG) has announced the pricing of its upsized public offering of 8,695,653 common shares at $5.75 per share, raising approximately $50 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 1,184,592 additional shares. The offering is expected to close on November 13, 2024. ACOG will begin trading on Nasdaq on November 12, 2024. Proceeds will fund the commercialization of ZUNVEYL for Alzheimer's Disease, pipeline development, CMC activities, and working capital.
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) reported financial results for Q2 and H1 2024, highlighting the FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease. The company's R&D expenses decreased to $0.9 million in Q2 and $1.9 million in H1 2024, down from $1.3 million and $2.4 million in the same periods of 2023. G&A expenses increased to $1.2 million in Q2 and $4.4 million in H1 2024, up from $0.6 million and $1.3 million in 2023. The Q2 2024 net loss was $2.1 million ($0.01 per share), and H1 2024 net loss was $7.1 million ($0.05 per share). Cash and cash equivalents stood at $1.0 million as of June 30, 2024.
FAQ
What is the current stock price of Alpha Cognition (ACOG)?
What is the market cap of Alpha Cognition (ACOG)?
